Biodexa Pharmaceuticals cash flow statement data for the quarter ended Jun 2025. This cash flow statement covers 23 quarters of results from Dec 2013 through Jun 2025, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2013 | Dec2014 | Dec2015 | Jun2016 | Dec2016 | Jun2017 | Dec2017 | Jun2018 | Dec2018 | Jun2019 | Dec2019 | Sep2020 | Dec2020 | Sep2021 | Dec2021 | Jun2022 | Sep2022 | Dec2022 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||
| Net Income | -48.61M | -14.54M | -21.95M | -16.33M | -23.04M | -31.57M | -5.04M | -8.55M | -4.62M | -10.14M | -4.83M | -9.29M | -4.57M | -5.30M | |||||||||
| Share-based Compensation | 0.05M | 0.12M | -0.09M | ||||||||||||||||||||
| Cash from Discontinued Operations | 2.24M | -6.92M | |||||||||||||||||||||
| Gains from Sales and Divestitures | 0.04M | ||||||||||||||||||||||
| Cash from Operations | 1.56M | 2.20M | -6.91M | -4.19M | -4.38M | 0.04M | |||||||||||||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||
| Amortization of Goodwill | 21.66M | ||||||||||||||||||||||
| Amortizatization of Intangibles | 0.08M | 0.11M | -0.20M | ||||||||||||||||||||
| Change in Working Capital | |||||||||||||||||||||||
| Change in Receivables | -0.30M | -1.16M | -0.28M | 0.53M | |||||||||||||||||||
| Change in Inventory | -0.29M | ||||||||||||||||||||||
| Change in Account Payables | 1.10M | 0.23M | -0.02M | ||||||||||||||||||||
| Change in Taxes | -11.39M | ||||||||||||||||||||||
| Investing Activities | |||||||||||||||||||||||
| Capital Expenditures | -1.67M | -0.03M | -0.11M | -0.12M | -0.26M | -0.25M | -0.04M | -0.04M | |||||||||||||||
| Sales of Property, Plant and Equipment | 0.06M | 0.01M | 0.01M | ||||||||||||||||||||
| Acquisitions | |||||||||||||||||||||||
| Cash from Investing Activities | -0.01M | -1.25M | -0.11M | -0.12M | -0.20M | -0.20M | -0.02M | -0.02M | |||||||||||||||
| Financing Activities | |||||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||
| Long-Term Debt Repayments | -0.29M | ||||||||||||||||||||||
| Short-Term Debt issuances | -3.92M | -4.11M | -0.14M | -0.14M | |||||||||||||||||||
| Misc. | |||||||||||||||||||||||
| Cash from Financing Activities | 0.05M | -0.01M | 15.73M | 0.48M | 0.51M | -0.11M | -0.11M | -0.10M | -0.09M | ||||||||||||||
| Exchange Rate Effect | -0.08M | 0.24M | 0.25M | -0.01M | -0.01M | ||||||||||||||||||
| Change in Cash | 8.61M | -8.55M | -8.97M | -4.64M | -4.50M | -4.49M | -4.26M | ||||||||||||||||
| Beginning Cash Balance | 23.23M | 22.50M | 17.99M | 3.01M | 3.01M | 13.76M | 14.43M | 10.49M | 10.17M | 12.66M | 12.44M | 11.80M | 3.55M | 7.54M | 2.23M | ||||||||
| Free Cash Flow | 3.23M | 2.20M | -6.91M | 0.03M | 0.11M | 0.12M | 0.26M | -3.93M | -4.34M | 0.07M | |||||||||||||
| Net Cash Flow | 1.54M | 2.24M | -6.92M | 14.48M | 0.37M | 0.39M | -0.32M | -4.50M | -4.49M | -0.08M |